A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity
Abstract This study aimed to find the association between four common clinical biomarkers and subsequent ICICT, developing a risk scoring strategy to assess the ICICT risk. Three terminals for ICICT were : Terminal 1, cancer therapy-related cardiomyopathies; Terminal 2, myocarditis or heart failure;...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-10-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-76829-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203788956139520 |
|---|---|
| author | Zhulu Chen Rui Lan Tao Ran Li Tao Yuxi Zhu Yanwei Li Chuan Zhang Min Mao Diansa Gao Zhong Zuo |
| author_facet | Zhulu Chen Rui Lan Tao Ran Li Tao Yuxi Zhu Yanwei Li Chuan Zhang Min Mao Diansa Gao Zhong Zuo |
| author_sort | Zhulu Chen |
| collection | DOAJ |
| description | Abstract This study aimed to find the association between four common clinical biomarkers and subsequent ICICT, developing a risk scoring strategy to assess the ICICT risk. Three terminals for ICICT were : Terminal 1, cancer therapy-related cardiomyopathies; Terminal 2, myocarditis or heart failure; and Terminal 3, myocarditis, heart failure, myocardial infarction, cerebral infarction, atrial fibrillation, or death. The thresholds were : N-terminal-pro-B-type-natriuretic-peptide ≥ 125 pg/mL, cardiac troponin T ≥ 6 ng/L, high-sensitivity C-reactive protein ≥ 3 mg/L, and coronary artery calcium score > 10 U. Each of the four abnormal biomarkers received 1 point. The links between biomarkers, score stage, and ICICT were analyzed. 375 patients with a mean follow-up of 1.91 years were included. All four biomarkers measured before immunotherapy were associated with a higher risk of developing ICICT. These scores were also associated with ICICT risk. The highest risk was the very high stage (score = 4) has 7.29, 8.83, and 7.02 folder higher risk compared to low risk group for Terminal 1–3, respectively. The cumulation of incidences also showed that the higher stages of score had an earlier onset and higher incidence of ICICT. 4 biomarkers and the scoring strategy enables clinicians to assess risk easily. |
| format | Article |
| id | doaj-art-2a34aefbc29e47d08f40a1dde80f1dba |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-2a34aefbc29e47d08f40a1dde80f1dba2025-08-20T02:11:25ZengNature PortfolioScientific Reports2045-23222024-10-0114111010.1038/s41598-024-76829-5A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicityZhulu Chen0Rui Lan1Tao Ran2Li Tao3Yuxi Zhu4Yanwei Li5Chuan Zhang6Min Mao7Diansa Gao8Zhong Zuo9Department of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Clinical Nutrition, School of Medicine, Chongqing University Cancer Hospital, Chongqing UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Radiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Oncology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Cardiology, The First Affiliated Hospital of Chongqing Medical UniversityAbstract This study aimed to find the association between four common clinical biomarkers and subsequent ICICT, developing a risk scoring strategy to assess the ICICT risk. Three terminals for ICICT were : Terminal 1, cancer therapy-related cardiomyopathies; Terminal 2, myocarditis or heart failure; and Terminal 3, myocarditis, heart failure, myocardial infarction, cerebral infarction, atrial fibrillation, or death. The thresholds were : N-terminal-pro-B-type-natriuretic-peptide ≥ 125 pg/mL, cardiac troponin T ≥ 6 ng/L, high-sensitivity C-reactive protein ≥ 3 mg/L, and coronary artery calcium score > 10 U. Each of the four abnormal biomarkers received 1 point. The links between biomarkers, score stage, and ICICT were analyzed. 375 patients with a mean follow-up of 1.91 years were included. All four biomarkers measured before immunotherapy were associated with a higher risk of developing ICICT. These scores were also associated with ICICT risk. The highest risk was the very high stage (score = 4) has 7.29, 8.83, and 7.02 folder higher risk compared to low risk group for Terminal 1–3, respectively. The cumulation of incidences also showed that the higher stages of score had an earlier onset and higher incidence of ICICT. 4 biomarkers and the scoring strategy enables clinicians to assess risk easily.https://doi.org/10.1038/s41598-024-76829-5Immune checkpoint inhibitorsCardiotoxicityMultimodality score strategyCardio-oncologyBiomarkers |
| spellingShingle | Zhulu Chen Rui Lan Tao Ran Li Tao Yuxi Zhu Yanwei Li Chuan Zhang Min Mao Diansa Gao Zhong Zuo A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity Scientific Reports Immune checkpoint inhibitors Cardiotoxicity Multimodality score strategy Cardio-oncology Biomarkers |
| title | A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity |
| title_full | A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity |
| title_fullStr | A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity |
| title_full_unstemmed | A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity |
| title_short | A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity |
| title_sort | multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity |
| topic | Immune checkpoint inhibitors Cardiotoxicity Multimodality score strategy Cardio-oncology Biomarkers |
| url | https://doi.org/10.1038/s41598-024-76829-5 |
| work_keys_str_mv | AT zhuluchen amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT ruilan amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT taoran amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT litao amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT yuxizhu amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT yanweili amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT chuanzhang amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT minmao amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT diansagao amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT zhongzuo amultimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT zhuluchen multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT ruilan multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT taoran multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT litao multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT yuxizhu multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT yanweili multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT chuanzhang multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT minmao multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT diansagao multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity AT zhongzuo multimodalityscorestrategyforassessingtheriskofimmunecheckpointinhibitorsrelatedcardiotoxicity |